Compounds > simvastatin
Page last updated: 2024-08-23

simvastatin and Cognition Disorders

simvastatin has been researched along with Cognition Disorders in 24 studies

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (33.33)29.6817
2010's16 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hamel, E; Tong, XK; Trigiani, LJ1
Kalonia, H; Kumar, A; Mishra, J; Sharma, N1
Catsman-Berrevoets, CE; de Wit, MC; Descheemaeker, MJ; Elgersma, Y; Legius, E; Moll, HA; Oostenbrink, R; Plasschaert, E; Renard, M; Rietman, AB; van der Vaart, T; Vergouwe, Y; Vogels, A1
Acosta, MT1
Caslake, M; Cooper, SA; Evans, J; Hassiotis, A; Jahoda, A; McConnachie, A; Morrison, J; Ring, H; Starr, J; Stiles, C; Sullivan, F1
Schetz, D; Sein Anand, J1
Chen, L; Chen, T; Li, G; Sha, S; Wang, C; Zhou, L1
Chan, MT; Gin, T; Mok, VC; Poon, WS; Siu, DY; Wong, A; Wong, GK; Zee, BC1
Hanratty, J; Livingstone, N; Macdonald, G; McShane, R1
Elgersma, Y; Legius, E; Moll, HA; Plasschaert, E; Rietman, AB; van der Vaart, T1
Amr, G; Azzaoui, R; Bordet, R; Delassus, L; Fossaert, E; Modine, T; Ouk, T; Tailleux, A1
Hamel, E; Ongali, B; Royea, J; Tong, XK1
Adeli, S; Hassanzadeh, G; Karimian, M; Tavoosidana, G; Zahmatkesh, M1
Borel, CO; Laskowitz, DT; Lombard, FW; Sheng, H; Takata, K; Warner, DS1
Chauhan, NB; Gatto, R1
Borre, Y; Douma, TN; Hendriksen, H; Olivier, B; Oosting, RS1
Can, ÖD; Özkay, ÜD; Öztürk, Y; Ulupınar, E; Yegin, B1
Balduini, W; Carloni, S; Cimino, M; De Simoni, MG; Mazzoni, E; Perego, C; Sironi, L1
Blennow, K; Hoglund, K; Lutjohann, D; Sjogren, M; Syversen, S; Thelen, KM; Vanderstichele, H; Vanmechelen, E; von Bergmann, K; Wallin, A1
McLachlan, C; Wang, PH; Wang, Q; Wong, PT1
Padala, KP; Padala, PR; Potter, JF1
Guyton, JR; Laskowitz, DT; Lynch, JR; Mace, B; Song, P; Wang, H; Warner, DS; Yang, HJ; Yates, RB1
Asthana, S; Atwood, CS; Blazel, HM; Carlsson, CM; Gleason, CE; Hermann, BP; Hess, TM; Johnson, SC; Koscik, RL; McBride, PE; Moreland, KA; Puglielli, L; Sager, MA; Schreiber, NT; Stein, JH1
Golomb, BA; Jaworski, B1

Reviews

2 review(s) available for simvastatin and Cognition Disorders

ArticleYear
Pharmacological interventions for cognitive decline in people with Down syndrome.
    The Cochrane database of systematic reviews, 2015, Oct-29, Issue:10

    Topics: Acetylcarnitine; Adult; Antioxidants; Cognition; Cognition Disorders; Donepezil; Down Syndrome; Humans; Indans; Memantine; Middle Aged; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Simvastatin

2015
Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.
    Cellular and molecular neurobiology, 2016, Volume: 36, Issue:2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Humans; Losartan; Simvastatin

2016

Trials

5 trial(s) available for simvastatin and Cognition Disorders

ArticleYear
Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
    The Lancet. Neurology, 2013, Volume: 12, Issue:11

    Topics: Adolescent; Child; Child Behavior Disorders; Cognition Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neurofibromatosis 1; Placebos; Simvastatin; Time Factors; Treatment Outcome

2013
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial.
    Trials, 2014, Jun-03, Volume: 15

    Topics: Age of Onset; Alzheimer Disease; Cognition Disorders; Down Syndrome; Feasibility Studies; Humans; Hypolipidemic Agents; Middle Aged; Neuropsychological Tests; Pilot Projects; Primary Prevention; Qualitative Research; Research Design; Simvastatin

2014
Cognitive outcome in acute simvastatin treatment for aneurysmal subarachnoid hemorrhage: A propensity matched analysis.
    Journal of the neurological sciences, 2015, Nov-15, Volume: 358, Issue:1-2

    Topics: Aged; Cognition Disorders; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Propensity Score; Simvastatin; Subarachnoid Hemorrhage; Treatment Outcome

2015
Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.
    Neurology, 2016, Jan-12, Volume: 86, Issue:2

    Topics: Adolescent; Attention; Behavior; Child; Cognition; Cognition Disorders; Female; Humans; Intelligence; Male; Neurofibromatosis 1; Neuropsychological Tests; Quality of Life; Simvastatin

2016
Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.
    Journal of Alzheimer's disease : JAD, 2008, Volume: 13, Issue:2

    Topics: Adult; Aged; Alzheimer Disease; Amyloid beta-Peptides; Anticholesteremic Agents; Apolipoprotein E4; Cognition Disorders; Double-Blind Method; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Neuropsychological Tests; Risk Factors; Severity of Illness Index; Simvastatin

2008

Other Studies

17 other study(ies) available for simvastatin and Cognition Disorders

ArticleYear
High cholesterol triggers white matter alterations and cognitive deficits in a mouse model of cerebrovascular disease: benefits of simvastatin.
    Cell death & disease, 2019, 01-28, Volume: 10, Issue:2

    Topics: Animals; Cerebrovascular Disorders; Cognition Disorders; Disease Models, Animal; Hypercholesterolemia; Male; Mice; Mice, Transgenic; Simvastatin; White Matter

2019
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
    European journal of pharmacology, 2013, Jun-05, Volume: 709, Issue:1-3

    Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; Huntington Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Malonates; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Simvastatin; Sulfones

2013
Challenges of cognitive research in neurofibromatosis type 1.
    The Lancet. Neurology, 2013, Volume: 12, Issue:11

    Topics: Child Behavior Disorders; Cognition Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neurofibromatosis 1; Simvastatin

2013
[Neurological disturbances in patient who ingested high doses of simvastatin].
    Przeglad lekarski, 2014, Volume: 71, Issue:9

    Topics: Atherosclerosis; Cognition Disorders; Drug Overdose; Dyslipidemias; Electromagnetic Fields; Humans; Male; Memory Disorders; Middle Aged; Occupational Diseases; Simvastatin; Sleep Wake Disorders

2014
Simvastatin prevents β-amyloid(25-35)-impaired neurogenesis in hippocampal dentate gyrus through α7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate.
    Neuropharmacology, 2015, Volume: 97

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Cognition Disorders; Dentate Gyrus; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Maze Learning; Mice, Inbred ICR; Neurogenesis; Neuroprotective Agents; Peptide Fragments; Phosphatidylinositol 3-Kinases; Polyisoprenyl Phosphates; Proto-Oncogene Proteins c-akt; Sesquiterpenes; Simvastatin

2015
Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass.
    Vascular pharmacology, 2016, Volume: 80

    Topics: Animals; Avoidance Learning; Cardiopulmonary Bypass; Cerebrovascular Disorders; Cognition Disorders; Endothelium, Vascular; Fenofibrate; Hemodynamics; Hypolipidemic Agents; Lipids; Male; Maze Learning; Neurons; Neuroprotective Agents; Rats, Sprague-Dawley; Simvastatin; Tumor Necrosis Factor-alpha; Vasodilation

2016
Simvastatin enhances the hippocampal klotho in a rat model of streptozotocin-induced cognitive decline.
    Progress in neuro-psychopharmacology & biological psychiatry, 2017, 01-04, Volume: 72

    Topics: Animals; Antibiotics, Antineoplastic; Cholesterol; Cognition Disorders; Disease Models, Animal; Glucuronidase; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraventricular; Klotho Proteins; Male; Maze Learning; Motor Activity; Rats; Rats, Wistar; Reaction Time; RNA, Messenger; Simvastatin; Streptozocin; Superoxide Dismutase

2017
Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage.
    Journal of neurosurgical anesthesiology, 2009, Volume: 21, Issue:4

    Topics: Animals; Cell Survival; Cerebral Arteries; Cerebrovascular Circulation; Cognition; Cognition Disorders; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Neurons; Postural Balance; Rats; Rats, Wistar; Simvastatin; Subarachnoid Hemorrhage

2009
Restoration of cognitive deficits after statin feeding in TBI.
    Restorative neurology and neuroscience, 2011, Volume: 29, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Brain Injuries; Cognition Disorders; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Learning; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Random Allocation; Recovery of Function; Simvastatin

2011
Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats.
    Psychopharmacology, 2011, Volume: 216, Issue:4

    Topics: Alzheimer Disease; Animals; Avoidance Learning; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuroprotective Agents; Olfactory Bulb; Rats; Rats, Sprague-Dawley; Simvastatin

2011
The effect of simvastatin treatment on behavioral parameters, cognitive performance, and hippocampal morphology in rats fed a standard or a high-fat diet.
    Behavioural pharmacology, 2012, Volume: 23, Issue:5-6

    Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Cognition Disorders; Diet, High-Fat; Female; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lactation; Male; Maternal Nutritional Physiological Phenomena; Neurogenesis; Neurons; Neuroprotective Agents; Nootropic Agents; Pregnancy; Rats; Rats, Sprague-Dawley; Simvastatin

2012
Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, and does
    Stroke, 2003, Volume: 34, Issue:8

    Topics: Animals; Animals, Newborn; Body Weight; Brain; Brain Chemistry; Cholesterol; Cognition Disorders; Disease Models, Animal; Drug Administration Schedule; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Ischemia, Brain; Interleukin-1; Male; Maze Learning; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha

2003
The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease.
    Dementia and geriatric cognitive disorders, 2005, Volume: 19, Issue:5-6

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Protein Precursor; Anticholesteremic Agents; Biomarkers; Brain Chemistry; Cholesterol; Cognition; Cognition Disorders; Female; Humans; Lipids; Male; Phosphorylation; Simvastatin; Sterols; tau Proteins

2005
Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats.
    Brain research, 2005, May-31, Volume: 1045, Issue:1-2

    Topics: Animals; Cognition Disorders; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Recovery of Function; Simvastatin; Substantia Nigra; Sympatholytics; Treatment Outcome

2005
Simvastatin-induced decline in cognition.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:10

    Topics: Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Humans; Male; Middle Aged; Simvastatin

2006
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
    Experimental neurology, 2007, Volume: 206, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Brain Edema; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Chemotaxis, Leukocyte; Cognition Disorders; Cytokines; Disease Models, Animal; Encephalitis; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Pyrroles; Recovery of Function; RNA, Messenger; Simvastatin; Treatment Outcome

2007
Statins and dementia.
    Archives of neurology, 2001, Volume: 58, Issue:7

    Topics: Anticholesteremic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Selection Bias; Simvastatin

2001